Ending diagnostic odysseys and inspiring hope
For patients with rare and complex conditions, physicians and other healthcare professionals need trusted answers. Our tests are developed through leading-edge research and unmatched clinical expertise, creating a diagnostics ecosystem that delivers insights that set a new standard in diagnostic care.
Successful patient outcomes are our priority, and we work with hospitals and physicians around the world to elevate diagnostic excellence everywhere. As part of Mayo Clinic’s healthcare system, we understand the best care is provided locally. We complement local expertise by working with clients and logistics organizations to optimize the specimen journey to our laboratories, enabling physicians to get the results they need and patients to remain at home, focused on healing.
Relentless pursuit of answers
Ongoing research propels test development at Mayo Clinic Laboratories, enabling innovative testing that delivers faster, reliable answers to confidently diagnose patients. Our test results not only equip physicians and patients with meaningful diagnostic, prognostic, and therapeutic insights, they also provide hope for a healthier future.
Experience and expertise you can trust
Mayo Clinic Laboratories’ scientists and physicians are leaders in their fields and able to consult on test selection, utilization, and results interpretation. The exchange of knowledge is a founding principle of Mayo Clinic, and we are committed to sharing lessons we’ve learned with our global collaborators through educational opportunities to help improve care delivery in local practices. This is supported through an expansive library of educational content, podcasts, and stories that showcase breakthroughs in test development and perspectives from Mayo Clinic experts.
Access to groundbreaking diagnostics
Driven by an instinct to innovate, we transform scientific discoveries into meaningful advancements in diagnostic testing. Supported by a robust network of Mayo Clinic physicians and scientists and forward-thinking laboratory partners, we foster access to new and advanced testing, much of which is unavailable elsewhere. This integration connects physicians and hospitals around the world with multiple innovative solutions all in one place to support better patient outcomes.
“We treat all of the specimens we receive with the same high degree of care and quality, regardless of where the sample is coming from. We could be testing a sample from a patient that lives in Rochester, Minnesota, or from someone that lives halfway across the world.”
Bobbi Pritt, M.D., Director of the Clinical Parasitology Laboratory
OUR DIFFERENCE
News and updates
The latest
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss updates on the Protecting Access to Medicare Act (PAMA) and other policy changes affecting clinical diagnostics. Later, Dr. Pritt welcomes Ann Moyer, M.D., Ph.D., a molecular genetic pathologist at Mayo Clinic and chair of the hereditary genetics practice, to explore how precision therapeutics are improving cancer treatments.
In this episode of “Lab Medicine Rounds,” host Justin Kreuter, M.D., interviews Eric Hsi, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic in Rochester, Minnesota, about the lab’s important role in healthcare.
In this special episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss the final rule issued by the U.S. Food and Drug Administration (FDA) on April 29, 2024, to make explicit its plan to regulate laboratory-developed tests (LDT) as medical devices under the Federal Food, Drug, and Cosmetic Act.
This page includes updates posted to Mayo Clinic Labs during the month of April.
As a successful outcome of the collaboration announced in 2023, Progentec’s proprietary biomarker blood tests for the proactive management of systemic lupus erythematosus are now available through Mayo Clinic Laboratories.
David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely impacts multiple organs and blood.
In this episode of Mayo Clinic Laboratories’ “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, speaks with outreach solutions strategists Ellen Dijkman Dulkes and Brianne Newton. Their discussion focuses on advocating for the laboratory, lab careers, and the value of lab testing.
The downtime process and form have been improved to provide clear guidance on the steps clients should take during downtime.
Mary Jo Williamson, chief administrative officer of Mayo Clinic Laboratories, joins the “Fierce Healthcare” podcast to discuss how organizations can cultivate resiliency and agility amidst a changing healthcare landscape.
Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.
The most successful laboratory outreach programs recognize the importance of serving multiple customers. From provider to patient to healthcare consumer, the laboratory has an opportunity to serve them all with high-quality results and excellent service. When aligning testing with community awareness and patient needs, the laboratory outreach program can strategically plan for future success.
In this episode of “Lab Medicine Rounds,” host Justin Kreuter, M.D., speaks with Chancey Christenson, M.D., about the lab's important role in healthcare.
Mayo Clinic Laboratories has marked a significant advancement in the fight against Alzheimer's disease with the introduction of an innovative diagnostic test. This noninvasive blood test accurately detects the p-Tau217 biomarker, indicative of amyloid beta accumulation in the brain. This test is set to transform the approach to Alzheimer's disease management, offering a convenient and less invasive alternative to traditional diagnostic methods.